| Autor: |
Ernst SM; Department of Respiratory Medicine, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., van Marion R; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., von der Thüsen JH; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., Dubbink HJ; Department of Pathology, Erasmus MC Cancer Institute, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands., Dingemans AC; Department of Respiratory Medicine, University Medical Center, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. Electronic address: a.dingemans@erasmusmc.nl. |
| Jazyk: |
angličtina |
| Zdroj: |
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Jul; Vol. 193, pp. 107844. Date of Electronic Publication: 2024 May 31. |
| DOI: |
10.1016/j.lungcan.2024.107844 |
| Abstrakt: |
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J.H. von der Thüsen reports receiving advisory board and speakers fees from Eli Lilly, BMS, MSD, AstraZeneca, Bayer, Janssen, Pfizer; outside the current work. H.J. Dubbink reports receiving translational research funding and support from AstraZeneca, MSD, Illumina; Advisory boards fees from Astellas, Abbvie, AstraZeneca, Bayer, Janssen, Lilly, MSD, Pfizer; Honorarium from AstraZeneca, Lilly, Novartis, Pfizer; and consultant fees from Bayer. A.C Dingemans reports receiving institutional fees from Roche, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Janssen, Chiezi, Amgen, Pfizer, Bayer, Takeda, Pharmamar, Sanofi and Daiichi; outside the current work. S.M. Ernst and R. van Marion report no disclosures. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect